Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2014; 20(26): 8351-8363
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8351
Nonalcoholic fatty liver disease and polycystic ovary syndrome
Evangeline Vassilatou
Evangeline Vassilatou, Endocrine Unit, 2nd Department of Internal Medicine - Propaedeutic, “Attikon” University Hospital, 12462 Athens, Greece
Author contributions: Vassilatou E solely contributed to this paper.
Correspondence to: Evangeline Vassilatou, MD, PhD, Endocrine Unit, 2nd Department of Internal Medicine - Propaedeutic, “Attikon” University Hospital, 1 Rimini st., 12462 Athens, Greece. niadas@hol.gr
Telephone: +30-210-5832584 Fax: +30-210-5832590
Received: October 28, 2013
Revised: February 17, 2014
Accepted: April 15, 2014
Published online: July 14, 2014
Processing time: 259 Days and 16.3 Hours
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption. Increased prevalence of NAFLD has been reported in patients with polycystic ovary syndrome (PCOS), one of the most common endocrinopathies in premenopausal women, which has been redefined as a reproductive and metabolic disorder after the recognition of the important role of insulin resistance in the pathophysiology of the syndrome. Obesity, in particular central adiposity and insulin resistance are considered as the main factors related to NAFLD in PCOS. Moreover, existing data support that androgen excess, which is the main feature of PCOS and is interrelated to insulin resistance, may be an additional contributing factor to the development of NAFLD. Although the natural history of NAFLD remains unclear and hepatic steatosis seems to be a relatively benign condition in most patients, limited data imply that advanced stage of liver disease is possibly more frequent in obese PCOS patients with NAFLD. PCOS patients, particularly obese patients with features of the metabolic syndrome, should be submitted to screening for NAFLD comprising assessment of serum aminotransferase levels and of hepatic steatosis by abdominal ultrasound. Lifestyle modifications including diet, weight loss and exercise are the most appropriate initial therapeutic interventions for PCOS patients with NAFLD. When pharmacologic therapy is considered, metformin may be used, although currently there is no medical therapy of proven benefit for NAFLD. Long-term follow up studies are needed to clarify clinical implications and guide appropriate diagnostic evaluation, follow-up protocol and optimal treatment for PCOS patients with NAFLD.

Keywords: Nonalcoholic fatty liver disease; Polycystic ovary syndrome; Insulin resistance; Obesity; Hyperandrogenism; Premenopausal women

Core tip: Nonalcoholic fatty liver disease (NAFLD) is frequent in patients with polycystic ovary syndrome (PCOS). Obesity and insulin resistance are considered as the main factors related to NAFLD in PCOS. Androgen excess may be an additional contributing factor to the development of NAFLD. Limited data imply that advanced stage of liver disease is possibly more frequent in obese PCOS patients with NAFLD. PCOS patients, particularly obese patients with the metabolic syndrome, should be screened for NAFLD. Long-term follow up studies are needed to clarify clinical implications, appropriate diagnostic evaluation and optimal treatment for PCOS patients with NAFLD.